Drugs for blood clots and diabetes backed by NICE
The National Industry for Health and Care Excellence (NICE) in the UK yesterday gave final recommendations for Bayer’s Xarelto and BMS-AZ’s Forxiga for use in England and Wales.
Bayer’s Xarelto (rivaroxaban) was deemed to be an efficient use of resources in the treatment of pulmonary embolism (PE), and to prevent recurrent deep vein thrombosis (DVT) and PE in adults who have undergone an acute incident of PE.
This recommendation will offer patients a simpler alternative to warfarin and will be used for patients who are unable to use warfarin.
Meanwhile, Forxiga (dapagliflozin) was given the green light to be used for some patients with type 2 diabetes to control blood sugar levels, however, it was recommended for use in a limited group of patients and on the condition that its price is reduced.
NICE backs blood clot and diabetes drugs (PM Live)
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.